-
Something wrong with this record ?
Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective
P. Hospodková, K. Gilíková, M. Barták, E. Marušáková, A. Tichopád
Status not-indexed Language English Country Switzerland
Document type Journal Article
Grant support
SGS23/197/OHK5/3T/17
Czech Technical University in Prague
NLK
Free Medical Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2013-01-01
Nursing & Allied Health Database (ProQuest)
from 2013-01-01
Public Health Database (ProQuest)
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009954
- 003
- CZ-PrNML
- 005
- 20230721095403.0
- 007
- ta
- 008
- 230707s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/healthcare11081179 $2 doi
- 035 __
- $a (PubMed)37108013
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hospodková, Petra $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000165428196
- 245 10
- $a Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective / $c P. Hospodková, K. Gilíková, M. Barták, E. Marušáková, A. Tichopád
- 520 9_
- $a Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gilíková, Klára $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000164243819
- 700 1_
- $a Barták, Miroslav $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000272656514
- 700 1_
- $a Marušáková, Elena $u Department of Public Health, Faculty of Health and Social Work, Trnava University, 917 01 Trnava, Slovakia $1 https://orcid.org/0009000544249849
- 700 1_
- $a Tichopád, Aleš $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000213080877
- 773 0_
- $w MED00200150 $t Healthcare (Basel, Switzerland) $x 2227-9032 $g Roč. 11, č. 8 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37108013 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095356 $b ABA008
- 999 __
- $a ok $b bmc $g 1958577 $s 1196218
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 11 $c 8 $e 20230419 $i 2227-9032 $m Healthcare $n Healthcare (Basel) $x MED00200150
- GRA __
- $a SGS23/197/OHK5/3T/17 $p Czech Technical University in Prague
- LZP __
- $a Pubmed-20230707